Undisclosed ADC therapeutic / GeneQuantum Healthcare, Aimed Bio - LARVOL DELTA

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate (PRNewswire) - "GeneQuantum Healthcare (Suzhou) Co., Ltd....has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic antibody drug conjugate (ADC)....The collaborating ADC is a first-in-class asset with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect. The resulting ADC is expected to treat brain and other cancers with huge unmet needs....The new drug is expected to enter IND in 2023."

IND • Licensing / partnership • Brain Cancer • CNS Tumor • Oncology • Solid Tumor